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Abstract: Adult T cell leukemia/lymphoma (ATL) represents an ideal model for targeted 
therapy because of intrinsic chemo-resistance of ATL cells and the presence of two well 
identified targets: the HTLV-I retrovirus and the viral oncoprotein Tax. The combination 
of zidovudine (AZT) and interferon-alpha (IFN) has a dramatic impact on survival of ATL 
patients. Although the mechanism of action remains unclear, arguments in favor or against 
a  direct  antiviral  effect  will  be  discussed.  Yet,  most  patients  relapse  and  alternative 
therapies are mandatory. IFN and arsenic trioxide induce Tax proteolysis, synergize to 
induce apoptosis in ATL cells and cure Tax-driven ATL in mice through specific targeting 
of leukemia initiating cell activity. These results provide a biological basis for the clinical 
success of arsenic/IFN/AZT therapy in ATL patients and suggest that both extinction of 
viral replication (AZT) and Tax degradation (arsenic/IFN) are needed to cure ATL. 
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1. The First Potential Target: HTLV-I Retrovirus 
The human T cell lymphotropic virus type I (HTLV-I) infects approximately 20 million individuals 
worldwide [1]. Endemic areas include Japan, the Caribbean, inter-tropical and South Africa, South 
America, some regions of Romania and the Middle East [2–4]. HTLV-I infection causes two major 
types  of  diseases:  HTLV-associated  myelopathy/tropical  spastic  paraparesis  (HAM/TSP),  an 
incapacitating inflammatory disease of the central nervous system, and adult T-cell leukemia/lymphoma 
(ATL),  a  distinct  peripheral  T-cell  malignancy  [5–7].  In  addition,  HTLV-I  infection  also  results  in 
immune suppression resulting in increased risk for coinfections such as Strongyloides Stercoralis [8]. 
ATL develops in a small percentage (4%) of HTLV-I-infected individuals after a long period of 
clinical latency following viral infection [9]. The late onset of ATL indicates that HTLV-I infection is 
not  sufficient  to  induce  T-cell  transformation  and  that  additional  genetic  mutations  favoring  the 
leukemogenic process are needed before the onset of ATL [10]. Yet, ATL is characterized by the 
monoclonal or oligoclonal integration of HTLV-I provirus in the tumor cells [11]. Typical ATL cells 
are characterized by unusual morphology with  a lobulated nucleus, known as “flower cells” [12]. 
These malignant lymphocytes are activated CD4+ CD25+ T cells with increased expression of the 
alpha chain of the interleukin-2 receptor [13]. In addition to the classical structural genes required for 
retroviral replication, the HTLV-1 genome encodes a series of auxiliary and regulatory proteins such 
as the viral transcriptional activator Tax and the HTLV-1 bZIP factor gene (HBZ), a viral protein 
encoded from the 3' LTR in the complementary strand of the proviral genome [14,15]. Both Tax and 
HBZ expression is linked to different stages of HTLV-I pathogenesis [16,17].  
HTLV-1 infects CD4+ and CD8+ T lymphocytes and can also efficiently infect dendritic cells [17]. 
The ubiquitous glucose transporter 1 and the neuropilin 1 were identified as members of the HTLV-I 
receptor complex [18–20]. Moreover, surface heparan sulfate proteoglycans were shown to be required 
for  efficient  virus  entry  [21,22].  Clonal  expansion  of  HTLV-infected  cells  mostly  relies  on  the 
promotion of cycling CD4+ T cells. Indeed, the proliferation of infected CD4+ cells, correlates with 
the level of Tax expression, resulting in accumulation of cellular defects [23,24].  
2. The Second Potential Target: The Viral Oncoprotein Tax 
In  addition to  its  effects on the viral  LTR, Tax has  pleiotropic  cellular functions  [1,25–27].  It 
stimulates the transcription of several cellular genes through activation of critical transcription factors 
such  as  nuclear  factor  kappa  B  (NF-κB)  [28–33],  cyclic  AMP  response  element-binding  protein 
(CREB),  serum  responsive  factor  (SRF),  and  activated  protein  1  (AP-1)  [34–37].  Recent  findings 
indicate that Tax post-translational modifications, namely ubiquitylation and SUMOylation, are critical 
for the constitutive activation of the NF-κB pathway [38–40]. 
Tax  also  represses  the  expression  of  cellular  genes  such  as  DNA  polymerase  β,  cyclin  A  and 
transforming  growth  factor  β  [41–43].  Moreover,  Tax  is  involved  in  the  regulation  of  apoptosis 
through the activation of apoptosis-suppressing genes such as Bcl-XL [44]. Tax inhibits the function of Viruses 2011, 3 
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tumor  suppressor  proteins  such  as  p53  and  p16,  interferes  with  cell  cycle  checkpoint control  and 
enhances the accumulation of mutations in HTLV-I infected cells through the repression of DNA 
repair [45–47]. Recent observations suggested that Tax also modulates the micro-RNA environment 
thereby adding another level of complexity to its cellular functions [48]. Altogether, these multiple 
activities of Tax cooperate to promote infected T-cell proliferation, generate cellular defects and lead 
to subsequent transformation.  
The oncogenic potential of Tax has been extensively studied. Tax was shown to transform a rat 
fibroblast cell line and immortalize primary T cells in vitro [49,50]. Importantly, tax-transgenic mice 
that express Tax under the control of the Lck-proximal promoter, which restricts Tax expression to 
immature thymocytes, develop a leukemia/lymphoma with striking ATL features that recapitulates the 
human  disease  [51].  Moreover,  reconstitution  of  NOD-SCID  mice  with  HTLV-1  tax-transduced 
human CD34+ cells resulted in the development of CD4+ lymphomas [52]. Altogether, these findings 
support an important role for Tax in the proliferation of infected cells, formally demonstrating that Tax 
alone can initiate ATL. It is noteworthy to mention however, that ATL occurs in less than 5% of 
HTLV-I infected individuals [9]. Whether continuous Tax expression is required for maintenance of 
the transformed phenotype is still controversial. 
3. Is Tax Really a Target in ATL?  
Based on its multiple effects, Tax was proposed to be an oncogene in ATL, but the fact that Tax 
protein expression is frequently undetectable in vivo has led to significant controversies. Indeed, viral 
expression is extremely limited in vivo and Tax protein expression is undetectable in the vast majority 
of ATL cells. Importantly, Tax expression has two major influences on HTLV-1 infected cells: first, as 
stated above, Tax recruits CD4+ T cells into the cell cycle and drives their proliferation and clonal 
expansion  [23,24];  on  the  other  hand,  Tax  is  highly  immunogenic  and  its  expression  induces  an 
immune  response  that  generates  cytotoxic  T  lymphocytes  (CTL)  chiefly  directed  against  this 
oncoprotein. Therefore, in order to escape this CTL-mediated lysis and to maintain viral persistence  
in vivo, HTLV-I infected cells and ATL cells frequently reduce the expression of Tax by several 
mechanisms.  For  example,  the  loss  of  5′-LTR  which  is  essential  for  viral  transcription,  and  the 
nonsense/mis-sense mutations of the tax gene, will both reduce viral expression. In addition, epigenetic 
changes in the 5′-LTR may also silence the transcription of viral genes [53–56]. Moreover, the HBZ 
protein, which is constitutively expressed in all ATL and HTLV-I infected cells, was shown to reduce 
Tax expression and Tax-mediated viral transcription [15,57]. Furthermore, HTLV-I auxiliary proteins 
such as p30 may play a critical role in slowing the replication of HTLV-I infected cells, possibly 
through  LTR  silencing  [58,59].  Interestingly,  mutations  in  Tax  MHC  class  I  recognition  site  also 
results in an escape of infected cells from immune recognition [54]. Therefore, it could be speculated 
that this repression in Tax expression is essential to protect infected cells from immune response and to 
maintain the virus in vivo. However, recent studies suggested that a loss of Tax expression does not 
only allow transformed T cells to evade CTL killing but also prevents Tax-induced mitotic aberrations 
that are detrimental to cell proliferation and therefore, to stabilize the karyotype of infected T cells [60].  
On the other hand, the lack of HTLV-I expression in vivo may be also explained by the existence of 
a viral reservoir, outside the blood compartment or by a transient or low-level expression of the Tax Viruses 2011, 3 
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protein undetectable by Western blot. Indeed, HTLV-1 infection of dendritic cells could provide a 
reservoir  for  HTLV-1  infection  [61].  These  dendritic  cells  likely  play  a  central  role  in  HTLV-I 
transmission, dissemination and persistence in vivo. The presence of other hidden viral reservoirs may 
be  also  suggested.  In  that  sense,  the  recapitulation  of  a  CD4+  T-cell  lymphoma  in  humanized-
NOD/SCID mice injected with CD34+ cells transduced with Tax [52] suggests that hematopoietic 
stem cells provide a viral reservoir in vivo.  
Interestingly, the level of Tax mRNA in murine ATLs derived from Tax transgenics is strikingly 
similar to the one found in human ATLs but 1000-fold less than in HTLV-I infected cell-lines [62]. 
This dramatic up-regulation of Tax in laboratory cell-lines may reflect some adaptation to ex vivo 
culture. In that sense, Tax expression is rapidly induced in ex vivo culture of primary HTLV-I infected 
lymphocytes. This strongly suggests that the microenvironment of ATL cells in vivo has an inhibitory 
effect on Tax expression [63]. Moreover, that Tax protein is not detected following transplantation of 
murine  ATL  cells  in  severely  immunodeficient  mice,  indicates  that  the  down-regulation  of  Tax 
expression  is  not  only  due  to  the  immune  pressure  against  cells  expressing  this  oncoprotein. 
Alternatively, this low level of Tax expression may be explained by the potential cellular toxicity of 
high  levels  of  Tax  oncoprotein.  Indeed,  in  previous  in  vitro  studies,  high  levels  of  Tax  had 
proapoptotic and anti-proliferative effects, whereas lower Tax levels stimulated cell cycle progression 
(reviewed in [64]). Moreover, previous reports demonstrated that Tax readily commits immortalized 
and transformed cells to senescence [65]. Therefore, one may suggest that ATL cells reduce in vivo 
Tax expression in order to escape Tax-induced cell death. Another explanation for this viral latency  
in vivo is a rapid destruction by the immune system of cells expressing HTLV-I proteins at the cell 
surface. Interestingly, HTLV-1 infected CD8+ T cells are themselves the subject of killing by virus 
specific CTL. Indeed, this fratricide among virus-specific CTLs could impair the immune control of 
HTLV-I contributing therefore to viral persistence in vivo [66]. 
Taking all these observations into account, it seems that there is dynamic equilibrium between viral 
persistence and the immune response that regulates the number of Tax-expressing cells and that Tax is 
indispensable for the transformation process induced in HTLV-I infected cells. Interestingly, using a 
specific  technique  that  permits  the  quantification  of  lymphocyte  turnover  in  humans  in  vivo,  
Asquith et al. provided evidence for continuous low-level of HTLV-1 expression in vivo [67]. They 
indeed  demonstrated  that  Tax  expression  is  correlated  with  CD4+CD45RO+  T  cell  proliferation 
therefore  suggesting  persistent  viral  gene  expression  in  vivo.  Increased  CD4+CD45RO+  cell 
proliferation would also increase the probability of acquiring mutations that could increase the risk of 
malignant transformation and the development of ATL.  
Although HBZ, that allows infected cells to evade an immune response through prevention of Tax 
overexpression [15], is needed to promote infected cell proliferation and persistence in the late steps of 
infection,  it  is  still  unknown  whether,  once  cells  are  transformed,  continuous  Tax  expression  is 
required  for  maintenance  of  the  leukemic  state.  HBZ  transgenics  develop  lymphoid  tumors  [68]. 
However, Tax transgenics and ATL cells are characterized by constitutive NF-κB activation [62], 
whereas NF-κB is not activated in malignant cells from HBZ transgenics. These indirect arguments 
suggest that the maintenance of the ATL phenotype requires continuous Tax expression. Viruses 2011, 3 
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4. Conventional Therapy for ATL 
The  diversity  in  prognosis  and  clinical  features  of  patients  with  ATL  led  to  the  Shimoyama 
classification of this disease into four clinical subtypes: acute, lymphoma, chronic and smoldering 
forms [69]. This classification is largely based on the extent of systemic leukemia, hypercalcemia and 
organ involvement. The chronic and smoldering subtypes are considered indolent, but eventually have 
poor long-term survival [70]. The acute and lymphoma forms generally have a worse prognosis mainly 
due  to  their  resistance  to  the  conventional  chemotherapies,  a  large  tumor  burden,  hypercalcemia, 
and/or frequent infectious complications as a result of a profound T-cell immunodeficiency [71,72]. 
Until recently, ATL was a nearly incurable disease with an overall median survival of less than one 
year in the aggressive forms. Complex combinations of chemotherapy regimen, such as the LSG15 
protocol,  resulted  in  an  improved  response  rate  particularly  in  the  lymphoma  subtype,  however,  
long-term  survival  remains  dismal  [73].  Promising  results  were  reported  in  selected  patients 
undergoing  allogeneic  stem  cell  transplantation,  possibly  reflecting  a  graft-versus-ATL  effect 
(reviewed  in  [74]).  Yet,  this  procedure  is  only  considered  in  eligible  young  ATL  patients  with 
available donors, with an extremely careful attention because of risk of opportunistic infections and 
significant transplant related mortality. Thus alternative therapies are still mandatory.  
5. Targeted Therapies for ATL 
5.1. Breakthrough in ATL Therapy: The Combination of Zidovudine and Interferon-Alpha 
An important advance in the treatment of ATL was initially reported in two preliminary phase II 
studies using the combination of an anti-retroviral agent zidovudine (AZT) and interferon-alpha (IFN). 
These initial reports accumulated promising evidence for the effectiveness of antiviral therapy in the 
treatment of ATL and suggested that this combination should be further evaluated. Hermine et al. 
demonstrated that the combination of AZT and IFN induces a rapid and durable response in five ATL 
patients [75]. Gill et al. showed that 11 out of 19 patients with acute or lymphoma ATL achieved 
major responses with the combination therapy (five complete remissions and six partial remissions) 
[76]. However, almost half of these patients had either relapsed or refractory disease. Bazarbachi et al. 
showed that the combination of AZT and IFN exhibited a high response rate and prolonged survival of 
previously untreated ATL patients [77]. However, in 2001, White et al. reported lower response rate in 
heavily  pretreated  ATL  patients.  Subsequently,  numerous  small  studies  confirmed  the  promising 
results achieved with AZT/IFN combination [78]. A British study reported that two-thirds of 15 ATL 
patients achieved and/or maintained a response to the combination of IFN and AZT [79]. One year 
later, the French ATL group published the results of a prospective phase II clinical trial with the use of 
AZT/IFN combination as first line therapy or after initial chemotherapy in 18 patients with aggressive 
ATL  (acute  and  lymphoma  subtypes)  [80].  The  initially  encouraging  results  of  the  combination 
AZT/IFN were confirmed in this phase II study with an overall response rate of 76%. Interestingly, the 
response rate was very high in previously untreated patients with acute ATL, since two CR and four 
PR (>95%) were observed in six out of seven patients. Moreover, these studies suggested that the 
synergistic effect between the two antiviral drugs AZT and IFN seems to be critical for a successful 
response. However, despite the benefit observed with this regimen, relapse occurred in most patients, Viruses 2011, 3 
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demonstrating that this combination did not cure ATL. Interestingly, the reintroduction of AZT/IFN 
induced second remissions in relapsed patients that were off therapy demonstrating that continuous 
maintenance  therapy  with  AZT/IFN  is  mandatory.  In  Iran,  a  recent  study  showed  that  AZT/IFN 
treatment  induced  a  high  response  rate  and  potentially  prolonged  survival  with  minimal  side  
effects [81]. In a recent prospective phase II study in the USA, 19 ATL patients received infusional 
chemotherapy (EPOCH regimen) until maximal response, followed by antiviral therapy with daily 
AZT,  lamivudine,  and  IFN.  However,  because  of  disease  progression,  only  six  patients  received 
antiviral therapy [82].
 Finally, a retrospective analysis in Martinique revealed a significant increase in 
ATL survival after 1995, when antiviral therapy was introduced [83].  
Although these multiple small studies demonstrated that AZT/IFN therapy is potentially beneficial 
for ATL, the impact of this antiviral combination on the long-term survival of ATL patients was still 
undetermined, until recently when we reported the results of a large worldwide meta-analysis on the 
use of IFN and AZT for ATL. In this analysis, we studied medical records of 254 patients with ATL 
who were treated in various countries (United States, United Kingdom, Martinique, and continental 
France). The combination of AZT and IFN had a dramatic impact on the survival of ATL patients, 
with a five-year overall survival (OS) of 46% for 75 patients who received first line antiviral therapy 
alone versus 14% for 132 patients who received first line chemotherapy with or without antiviral 
maintenance.  In  acute  ATL,  first-line  antiviral  therapy  alone  resulted  in  a  significant  survival 
advantage  (five-year  OS  of  28%)  as  compared  with  first-line  chemotherapy  with  or  without 
maintenance antiviral therapy (five-year OS of 10%). Achievement of CR with antiviral therapy in 
acute ATL resulted in 82%  five-year survival.  Importantly, patients with ATL lymphoma did not 
benefit from the combination of AZT and IFN indicating that standard chemotherapy should remain 
the  mainstay  of  treatment  for  this  subtype.  Finally,  first-line  AZT/IFN  therapy  in  chronic-  and 
smoldering-type ATL resulted in 100% OS at a median follow-up time of five years [84]. These are 
very  promising  results  specifically  when  compared  to  the results  reported  in  a  recently  published 
Japanese study in which the five-year OS was as low as 47% in patients with indolent ATL that were 
managed by a watchful waiting policy until disease progression or by chemotherapy [85].  
Therefore, the results of this meta-analysis led to the conclusion that the treatment of ATL using the 
combination of AZT and IFN induces high response and CR rates and significantly prolongs survival 
particularly in acute, chronic, and smoldering types of ATL, but not in lymphoma ATL. Accordingly, 
this  highly  beneficial  combination  should  be  considered  as  the  gold  standard  first-line  therapy  in 
leukemic subtypes of ATL. This combination is mostly effective as initial therapy but less effective 
after prior treatment with chemotherapy, most likely due to the selection of a tumor clone with mutated 
p53 when first line chemotherapy is used.  
In summary, the combination of AZT and IFN has clearly changed the natural history of ATL 
through achievement of a significantly improved long-term survival in patients with smoldering and 
chronic ATL as well as a subset of patients with acute ATL and wild type p53 status. Unfortunately, 
most  patients  eventually  relapsed,  suggesting  that  AZT/IFN  could  not  cure  ATL  and  that  new 
therapeutic approaches are still needed. Viruses 2011, 3 
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5.2. The AZT/IFN Combination: Is it an Antiviral Therapy? 
The success of this potentially antiretroviral approach in the treatment of ATL raises important 
questions on the mechanism of action of this combination. Zidovudine, formerly called azidothymidine 
(AZT), is an antiviral pyrimidine nucleoside analogue that inhibits the reverse transcriptase of the 
human  immunodeficiency  virus  (HIV)  and the HTLV-1 virus  [86]. AZT does  not  have a  general 
antineoplastic activity because it is a poor substrate for mammalian DNA polymerase-α [71]. On the 
other hand, interferons (IFN) are a family of glycoproteins whose mechanism of action is complex and 
not well understood. IFN have potent broad-spectrum antiviral effect. They activate several interferon-
responsive genes that have antiviral activity. IFN have also an antiproliferative effect and can inhibit 
the cell growth of several tumor cells. Moreover, IFN have an immunomodulatory effect and may 
therefore stimulate the immune system. Furthermore, IFN activate several immune cells like natural 
killer cells and macrophages, increase antigen presentation to lymphocytes, and induce the resistance 
of host cells to viral infection helping in slowing down tumor cell growth [87]. Finally, a recent report 
demonstrated that plasmacytoid dendritic cells respond to cell-free HTLV-1 by producing high levels 
of IFN and by mobilizing TRAIL on cell surface after TLR7 triggering [88]. 
Several arguments are in favor of an antiviral effect of the AZT/IFN combination. In a rabbit model 
of  ATL,  AZT  inhibited  HTLV-I  proviral load  [89].  Moreover,  AZT  inhibited  the  transmission  of 
HTLV-I to adult peripheral blood mononuclear cells in vitro and blocked the transformation of these 
normal blood lymphocytes when co-cultured with an HTLV-I transformed cell line [90]. Recently, it 
was shown that a combination of AZT with an inhibitor of histone deacetylases decreases the proviral 
load and increases virus-specific cytotoxic T-cell population in a series of baboons naturally infected 
with simian T-lymphotropic virus type 1 (STLV-1) confirming the antiviral effect of AZT [91]. Recent 
studies demonstrated that IFN inhibited HTLV-I virus assembly by preventing targeting of viral Gag 
proteins  to  the  rafts  in  the  plasma  membrane,  demonstrating  its  antiviral  effect  [92].  Among  its 
multiple biological effects, IFN has an immunomodulatory effect that should be also considered. As 
stated before, HTLV-I infected individuals are known to have a strong CTL response against cells that 
express  the  Tax  protein  [93]  and  IFN  may  induce  the  expression  of  viral  antigens  or  major 
histocompatibility complex molecules to enhance the CTL response against the HTLV-I infected cells. 
Interestingly, recent reports indicate that HTLV-1 evades type I IFN antiviral signaling by inducing the 
suppressor  of  cytokine  signaling  1  (SOCS1).  Of  particular  interest,  SOCS1  was  upregulated  in 
HAM/TSP patients and asymptomatic carriers but not in ATL [94]. 
On the other hand, a potentially cytotoxic effect of the AZT/IFN combination on leukemic cells 
cannot be excluded. The addition of IFN and AZT inhibited cell growth of myeloid leukemia cell lines, 
in vitro [95]. However, we have reported compelling evidence that the therapeutic effect of AZT/IFN 
is not through a direct cytotoxic effect of these drugs on the ATL leukemic cells. Indeed, AZT, IFN 
and their combination failed to induce any significant inhibition of cell proliferation, cell cycle arrest 
or apoptosis of HTLV-I positive cell lines even in long-term culture. Furthermore, we observed no  
in  vitro  cytotoxic  effect  of  the  AZT/IFN  combination  on  fresh  leukemic  cells  derived  from  an  
acute ATL patient at diagnosis despite achievement of in vivo complete remission using the same 
therapy [96]. Viruses 2011, 3 
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Datta et al. demonstrated that treatment of HTLV-1 infected cells with AZT leads to telomere 
shortening, induction of cellular senescence and reactivation of p53 functional activities. They also 
showed a direct correlation between patient’s response to AZT/IFN and p53 status [97]. Accordingly, 
the analysis of p53 sequence in the malignant cells before the beginning of AZT/IFN treatment could 
be highly beneficial to predict disease outcome. Patients with mutated p53 that may not respond to 
AZT/IFN treatment should be treated with other alternative ATL treatments. However, the lack of 
efficacy of AZT outside the settings of virus-associated malignancies argues against the hypothesis 
that telomerase and p53 are the main targets of this drug. In that sense, the combination AZT/IFN is 
not  effective  in  Tax-transgenic  murine  ATL  [98].  In  this  model,  Tax  expression  is  under  the  lck 
promoter and there is no viral replication.  
One  may  argue  that  the  HTLV-I  virus  does  not  replicate  in  ATL  cells.  To  reconciliate  these 
contradictory findings, we can hypothesize that the AZT/IFN combination targets viral replication 
outside ATL cells, such as in dendritic cells or other cell types in which a dynamic continuous viral 
replication  occurs.  In  that  case,  this  viral  replication  can  provide  the  microenvironment  that  is 
mandatory for survival of ATL cells through direct cell-cell communication or paracrine stimulation 
through  secreted  Tax  or  various  cytokines/chemokines  as  reported  for  chronic  lymphocytic  
leukemia [99]. This explains the impossibility to culture ATL cells in vitro and the effectiveness of the 
AZT/IFN combination in vivo but not in vitro. Similarly, the AZT/IFN combination, through inhibition 
of de novo infection of circulating CD8+ lymphocytes, that are subject to killing by virus specific CTL 
[66], may protect the immune system from the fratricide among these virus-specific CTLs, allowing 
therefore disease control by the immune system. 
Finally, from a philosophical point of view, it is interesting to note that the only malignancy in 
which  the  antiviral  drug  AZT  is  highly  effective  is  ATL  which  is  the  only  human  malignancy 
secondary to a retroviral infection. In summary, even though the mechanism of action of AZT/IFN has 
not been fully elucidated yet, multiple clinical trials have clearly shown that the combination of AZT 
and IFN improves the survival of ATL patients but cannot cure ATL.  
5.3. Targeting ATL Leukemia Initiating Activity: The Combination of Arsenic Trioxide and IFN 
Besides the combination of AZT and IFN, one of the most promising targeted therapies against 
ATL  is  the  combination  of  IFN  and  arsenic  trioxide,  a  very  effective  treatment  against  acute 
promyelocytic leukemia (APL) [100,101]. In fact, it all started around ten years ago when we first 
demonstrated that the combination of arsenic and IFN act synergistically to induce cell cycle arrest and 
apoptosis,  specifically  in  HTLV-I  transformed  cells  and  fresh  ATL  leukemia  cells,  providing  a 
biological basis for arsenic/IFN treatment in ATL [102,103]. At the molecular level, we reported that 
the  arsenic/IFN  combination  kills  ATL  derived  cells  through  rapid  reversal  of  the  constitutive 
activation of NF-κB and delayed shut down of cell cycle-regulated genes secondary to Tax degradation 
by the proteasome that was concomitant with cell death induction, thus indicating the importance of 
continuous Tax expression for ATL cell survival [104,105]. These results prompted us to investigate 
the efficacy of this combination in ATL patients. Therefore, we initiated a phase II clinical trial of 
arsenic/IFN in seven patients with relapsed or refractory ATL after AZT/IFN/chemotherapy. Four 
patients responded with one complete remission and three partial remissions [106]. One patient was Viruses 2011, 3 
 
 
758 
still alive and free of disease five years later. Despite the poor prognosis of the selected patients 
enrolled  in  this  study,  we  demonstrated  that  treatment  with  arsenic/IFN  is  feasible  and  exhibits  
anti-leukemic effect. Later in 2007, Ishitsuka  et al. reported that arsenic/IFN combination yielded 
clinical results in two moderately-aggressive ATL patients [107]. 
The efficacy and the toxicity of this combined treatment were also evaluated in HTLV-1-infected 
squirrel monkeys and HTLV-1 infected cell lines derived from it. It was shown that arsenic/IFN can 
induce growth arrest in HTLV-1-transformed monkey T-cell lines in vitro and reduce the total number 
of circulating HTLV-1 flower cells in the infected monkeys with chronic ATL-like disease [108]. 
We recently reported the results of a prospective phase II trial in which arsenic was added to the 
combination of AZT and IFN in newly diagnosed chronic ATL. Interestingly, all 10 patients enrolled 
in this trial responded, including seven patients who achieved CR, two patients who achieved very 
good partial response (clinical and biologic CR except for the presence of more than 5% atypical 
lymphocytes on peripheral blood smear), and one patient achieved partial response. Side effects were 
moderate and no relapse was noted at the time of reporting [109]. These encouraging results suggest 
that the triple combination of arsenic, AZT and IFN is a promising approach that should be further 
evaluated in the first line therapy of ATL.  
To investigate the molecular mechanism of therapeutic action in vivo, we used Tax transgenic mice 
that develop a disease with striking ATL features including circulating ATL like flower cells, massive 
organ  infiltration,  high  LDH,  malignant  hypercalcemia  and  constitutive  NF-kB  activation  in  the 
leukemic  cells  [51].  We  recently  reported  that  the  combination  of  arsenic  trioxide  and  IFN  cures  
Tax-driven murine ATLs through selective targeting of leukemia initiating cell (LIC) activity. Indeed, 
unexpectedly, ATL cells did not respond to arsenic and IFN by apoptosis and/or cell cycle arrest  
in vivo and therefore this regimen does not induce rapid tumor regression or massive cell death in 
treated animals. On the other hand, we showed that this combination therapy used in primary mice 
immediately reduces leukemia transplantation into untreated secondary recipients and totally abrogates 
leukemia transplantation into untreated tertiary recipients. In other words, the primary tumor continues 
to  grow  and  only  exhausts  much  later,  due  to  the  specific  targeting  of  LIC  activity.  Adding  the 
proteasome inhibitor bortezomib essentially blocks the degradation of Tax triggered by the arsenic/IFN 
combination, and eliminates the enhancement of survival in secondary and tertiary recipients. This 
reversal of ATL LIC eradication by proteasome inhibition is a significant indication that ATL cells are 
addicted to continuous Tax expression for their LIC activity (stemness) but not for their short-term 
tumor growth [62].  
5.4. Are We Really Targeting Tax? 
Proteasome-mediated  degradation  of  Tax  and  targeting  of  ATL  LIC  activity  by  arsenic/IFN 
combination is reminiscent of the proteasome-mediated degradation of PML-RAR and targeting of 
APL LIC by arsenic in APL [62,101]. But does LIC eradication by arsenic/IFN really rely on Tax 
degradation?  
As previously described, microarray analysis of the gene expression profile shows that both arsenic 
and arsenic/IFN specifically block the transcription of NF-κB dependent genes which results in the 
reversal of NF-κB activation [104]. Although activation of the NF-κB pathway has been reported to Viruses 2011, 3 
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play a crucial role in the proliferation of ATL leukemia cells, its sole inhibition by arsenic alone is not 
enough to explain the in vivo effects of the combination. Moreover, we have also demonstrated that 
bortezomib,  triggers  NF-κB  inhibition  in  ATL  cells  [110].  However,  neither  arsenic  alone  nor 
bortezomib alone are sufficient to eradicate ATL LIC activity [62].  
One may argue that there is low or even no expression of Tax in vivo, so how to explain the in vivo 
efficacy  of the arsenic/IFN combination?  As discussed  previously, the issue  of Tax  expression in 
HTLV infected cells or in ATL cells is still controversial. Strong evidence in favor of Tax expression 
is the existence of Tax specific antibodies in the serum of ATL patients and the presence of the  
Tax-specific CD8+ T cells recently demonstrated in ATL patients (reviewed in [111,112]). Moreover, 
although Tax is not detectable in freshly harvested cells, it is up regulated once the cells are cultured  
ex vivo [113] strongly suggesting that Tax is expressed in at least some ATL cells. In that sense, a 
recent report indicate that human and mouse stromal cells, such as epithelial cells and fibroblasts, 
suppressed HTLV-1 expression in ATL and non-ATL HTLV-1-infected cells. When infected cells 
were  reisolated  from  the  cocultures,  viral  expression  was  restored  to  the  original  level  over  the 
following 48 h. Spontaneous induction of HTLV-1 expression in primary ATL cells in the first 24 h of 
culture was also inhibited by coculture with stromal cells. Indeed, coculture of HTLV-1-infected cells 
and stromal cells induced type I IFN responses. These findings indicate that the innate immune system 
suppresses HTLV-1 expression in vivo, at least through type I IFN [63]. 
Although other viral factors can promote pathogenesis such as HBZ, tax-transgenic mice develop a 
disease that strikingly recapitulates human ATL [68]. Conversely, although HBZ transgenics develop 
lymphoid tumors, these transformed cells are devoted from NF-kB activation and hence are different 
from ATL cells. Moreover, in Tax-transgenic mice, although tax mRNA is detectable, there is no 
constitutive detectable expression of the Tax protein in the transformed T cells. Interestingly, the level 
of tax expression in these transgenic mice is very similar to the level found in ATL patients and  
1000-times less than that in cell lines [62] indicating that high levels of Tax may be toxic in vivo and 
only low levels are needed for transformation.  
The  mechanism  as  to  how  viral  expression  is  maintained  in  vivo  in  this  latent  form  is  not 
understood. One possible explanation is the existence of a viral reservoir in vivo, which may involve 
dendritic cells. In that sense, Jones et al., 2008 [61] showed that HTLV-I can infect dendritic cells that 
can efficiently transfer virus to autologous primary CD4+ cells indicating that dendritic cells have a 
central role in HTLV-I transmission, dissemination and persistence in vivo.  
Overall, based on the high specificity of the IFN/arsenic combination to both HTLV-I-infected cells 
and  Tax-driven  murine  ATL,  it  is  most  likely  that  therapy-induced  loss  of  the  driving  oncogene 
underlies therapy responses. Hence, we suggest the existence of a hierarchy among genetic defects in 
ATL: Tax clearly initiates the disease while HBZ and other secondary somatic mutations in cellular 
genes favor its progression. As for many other types of leukemia, secondary events are unlikely to be 
ideal  targets  for  curative  therapies  whereas  earlier  genetic  events  are  the  most  important  for  the 
maintenance of the leukemic clone proliferation and survival. Our results suggest that Tax is required 
for  both  initiation  of  ATL  and  for  the  maintenance  of  the  ATL  LIC  activity  (stemness)  but  is 
dispensable for short-term growth. Hence, the combination of arsenic and IFN cures ATL through 
proteasome-dependent  oncoprotein  degradation  resulting  in  selective  eradication  of  the  ATL 
LIC activity.  Viruses 2011, 3 
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6. Conclusion 
On  the  basis  of  these  findings,  the  triple  combination  of  AZT,  IFN  and  arsenic  represents  an 
appealing first-line therapy of ATL. In that sense, three out of six chronic ATL patients who stopped 
therapy after achieving complete remission with the triple combination of AZT, IFN and arsenic, 
remained in CR after 18 months, an unprecedented finding. Furthermore, the use of the IFN/arsenic 
combination as a consolidation therapy after chemotherapy allowed very long lasting remissions [114], 
suggesting that it can efficiently target ATL LIC activity. However, these findings are still preliminary 
and  need  confirmation  in  larger  studies  before  they  can  be  routinely  used  in  ATL  therapy.  In 
conclusion, our results raise hopes that extinction of viral replication (AZT/IFN) and Tax degradation 
with subsequent eradication of LIC activity (arsenic/IFN) may eradicate the disease resulting in ATL 
cure rather than long-term disease control.  
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